Abstract: Objective The aim of this study was to summarize the clinical characteristics and analyze the risk factors of drug-induced liver injury(DILI) caused by antituberculosis therapy. Methods 558 patients receiving antituberculosis therapy in our hospital were retrospectively analyzed in this study, and 69 patients had DILI. The incidences and laboratory indexes of patients with different antituberculosis regimen were compared and the risk factors affecting the incidence of DILI were determined by Logistic analysis. Results During the anti-tuberculosis process, 69 (12.4%) out of 558 patients with tuberculosis developed DILI; out of 442 nave patients, the incidence of DILI was 5.4%, much lower than 35.9% in 103 relapse patients or 61.5% (P<0.05) in 13 patients with multi-drug resistance (MDR); serum alanine aminotransferase, aspartate aminotransferase, total bilirubin, glutamyltranspeptidase and alkaline phosphatase peak levels in the 69 patients with DILI were 152.1±9.6 U/L, 174.8±15.4 U/L, 94.8±8.6μmol/L, 131.3±10.2 U/L and 152.0±14.3 U/L; the incidences of DILI in patients with different age, liver disease history, alcohol abuse and anti-tuberculosis regimen were significantly different and liver disease history, relapse and patients with MDR were the independent risk factors for DILI occurrence (P<0.05). Conclusion The incidence rate of DILI is different in patients with different anti-tuberculosis treatment, and the clinicians must take the risk factors into consideration in order to avoid the harmful elements and protect the patients to finish the anti-tuberculosis regimen.

Key words: Drug-induced liver injury, Anti-tuberculosis therapy, Multiple drug resistant, Relapse, Risk factors